Kiniksa Pharmaceuticals International (MEX:KNSAN) Long-Term Debt: MXN0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KNSAN Kiniksa Pharmaceuticals International PLC MEX:KNSAN
50 GF Score
Price MXN754.37
GF Value MXN549.40
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Long-Term Debt?

Kiniksa Pharmaceuticals International MEX:KNSAN 50 Long-Term Debt is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:KNSAN with a GF Score™ of 50/100 and a GF Value™ of MXN549.40. The stock has 4 warning signs investors should review.

Kiniksa Pharmaceuticals International's Long-Term Debt for the quarter that ended in Jun. 2026 was MXN0 Mil.

Kiniksa Pharmaceuticals International  (MEX:KNSAN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Kiniksa Pharmaceuticals International Long-Term Debt Related Terms

Kiniksa Pharmaceuticals International Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Kiniksa Pharmaceuticals International's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Long-Term Debt Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kiniksa Pharmaceuticals International Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:KNSAN
50GF Score
Kiniksa Pharmaceuticals International PLC MEX:KNSAN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of MXN0 Mil mean?
Kiniksa Pharmaceuticals International (MEX:KNSAN) has a Long-Term Debt of MXN0 Mil as of Jun. 2026.
Is Kiniksa Pharmaceuticals International's Long-Term Debt too high?
Kiniksa Pharmaceuticals International's current Long-Term Debt is MXN0 Mil. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Long-Term Debt compare to AMRX and LQDA?
Kiniksa Pharmaceuticals International's Long-Term Debt of MXN0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Kiniksa Pharmaceuticals International's current Long-Term Debt is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Kiniksa Pharmaceuticals International (MEX:KNSAN) has a current Long-Term Debt of MXN0 Mil. The stock's GF Value™ is MXN549.40, compared to a current price of MXN754.37 — trading 37.3% above its estimated fair value. The current Long-Term Debt is MXN0 Mil. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (MEX:KNSAN), the current Long-Term Debt is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (MEX:KNSAN) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of MXN754.37 is trading 37.3% above its estimated GF Value™ of MXN549.40.

Key valuation signals for MEX:KNSAN:

  • Long-Term Debt: MXN0 Mil
  • GF Value™: MXN549.40 vs. price of MXN754.37 (37.3% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the MEX:KNSAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Other Exchanges KNSA:USA
Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score

Get the complete analysis for MEX:KNSAN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN754.37
Price
MXN549.40
GF Value